Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | 2C10H18NO8.Ca |
| Molecular Weight | 600.582 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 8 / 8 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[Ca++].CN(C)CC(=O)OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.CN(C)CC(=O)OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O
InChI
InChIKey=JWLAOERSRUNGEF-JQVJEGKNSA-L
InChI=1S/2C10H19NO8.Ca/c2*1-11(2)3-6(13)19-4-5(12)7(14)8(15)9(16)10(17)18;/h2*5,7-9,12,14-16H,3-4H2,1-2H3,(H,17,18);/q;;+2/p-2/t2*5-,7-,8+,9-;/m11./s1
| Molecular Formula | Ca |
| Molecular Weight | 40.078 |
| Charge | 2 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | C10H18NO8 |
| Molecular Weight | 280.2518 |
| Charge | -1 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 4 / 4 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
DescriptionSources: https://www.drugs.com/inactive/calcium-phosphate-dibasic-anhydrous-463.htmlhttp://apps.who.int/iris/bitstream/10665/43579/1/9789241530729_eng.pdfhttp://www.globalrph.com/calcium_supplements.htm | https://www.ncbi.nlm.nih.gov/pubmed/26265479Curator's Comment: description was created based on several sources, including
https://www.alfa.com/en/catalog/043674/
Sources: https://www.drugs.com/inactive/calcium-phosphate-dibasic-anhydrous-463.htmlhttp://apps.who.int/iris/bitstream/10665/43579/1/9789241530729_eng.pdfhttp://www.globalrph.com/calcium_supplements.htm | https://www.ncbi.nlm.nih.gov/pubmed/26265479
Curator's Comment: description was created based on several sources, including
https://www.alfa.com/en/catalog/043674/
Calcium lactate is the salt that consists of two lactate anions for each calcium cation (Ca2+); this salt is used as a calcium supplement to treat hypocalcemia. However, as a source of free calcium, this salt is less convenient than calcium citrate. Calcium lactate inhalation powder also called as PUR118 participated in phase I clinical trials to determine whether this formulation was safe and tolerable in a population of subjects with Cystic Fibrosis (CF). PUR118 also was used in another clinical trials to evaluate its effect on ozone-induced airway Inflammation in healthy normal volunteers in case of Chronic Obstructive Pulmonary Disease (COPD). The obtained results revealed that PUR118 reduced the severity of acute exacerbations in COPD and CF and had the beneficial impacts on mortality, morbidity, and quality of life in affected individuals. However, both studies were discontinued.
Originator
Approval Year
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Unknown Approved UseUnknown |
|||
| Palliative | Unknown Approved UseUnknown |
|||
| Palliative | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseHypocalcemia, chronic (treatment) — Oral calcium supplements provide a source of calcium ion for treating calcium depletion occurring in conditions such as chronic hypoparathyroidism, pseudohypoparathyroidism, osteomalacia, rickets, chronic renal failure, and hypocalcemia secondary to the administration of anticonvulsant medications. When chronic hypocalcemia is due to vitamin D deficiency, oral calcium salts may be administered concomitantly with vitamin D analogs. However, calcium phosphate should not be used in patients with hypoparathyroidism or renal failure, since phosphate levels may be too high and giving more phosphate would exacerbate the condition. Calcium supplements should not be used in hyperparathyroidism, unless the need for a calcium supplement is high and the patient is carefully monitored. For treatment of hypocalcemia, supplementation is preferred |
PubMed
| Title | Date | PubMed |
|---|---|---|
| [Early stage of cardiomyopathy: mechanisms of damage and compensation]. | 1999 Jul |
|
| C-reactive protein in the hemolymph of Achatina fulica: interrelationship with sex steroids and metallothionein. | 2000 Apr |
|
| Cytosolic [Ca(2+)] modulates basal GLUT1 activity and plays a permissive role in its activation by metabolic stress and insulin in rat epithelial cells. | 2000 Aug |
|
| Regulation of Na/K-ATPase beta1-subunit gene expression by ouabain and other hypertrophic stimuli in neonatal rat cardiac myocytes. | 2000 Dec |
|
| Inactivation properties of human recombinant class E calcium channels. | 2000 Feb |
|
| Effect of ADP and ionic strength on the kinetic and motile properties of recombinant mouse myosin V. | 2000 Feb 11 |
|
| Neuropeptide Y (NPY) potentiates phenylephrine-induced mitogen-activated protein kinase activation in primary cardiomyocytes via NPY Y5 receptors. | 2000 Feb 15 |
|
| Hepatocyte growth factor disrupts cell contact and stimulates an increase in type 3 inositol triphosphate receptor expression, intracellular calcium levels, and apoptosis of rat ovarian surface epithelial cells. | 2000 Jun |
|
| A family of gamma-like calcium channel subunits. | 2000 Mar 24 |
|
| Polyoxygenated dysidea sterols that inhibit the binding of [I125] IL-8 to the human recombinant IL-8 receptor type A. | 2000 May |
|
| Dual regulation of leptin secretion: intracellular energy and calcium dependence of regulated pathway. | 2000 May |
|
| Inhibition of proteolysis by a cyclooxygenase inhibitor, indomethacin. | 2000 Nov |
|
| Pharmacological blockade of ERG K(+) channels and Ca(2+) influx through store-operated channels exerts opposite effects on intracellular Ca(2+) oscillations in pituitary GH(3) cells. | 2000 Nov |
|
| Calmodulin kinases II and IV and calcineurin are involved in leukemia inhibitory factor-induced cardiac hypertrophy in rats. | 2000 Nov 10 |
|
| Mechanism of extracellular calcium regulation of intestinal epithelial tight junction permeability: role of cytoskeletal involvement. | 2000 Oct 15 |
|
| High-calcium diet enhances vasorelaxation in nitric oxide-deficient hypertension. | 2000 Sep |
|
| Chemokines induce eosinophil degranulation through CCR-3. | 2000 Sep |
|
| Pilocarpine-induced status epilepticus causes N-methyl-D-aspartate receptor-dependent inhibition of microsomal Mg(2+)/Ca(2+) ATPase-mediated Ca(2+) uptake. | 2000 Sep |
|
| Characterization of the human cysteinyl leukotriene 2 receptor. | 2000 Sep 29 |
|
| Ca2+-induced contraction of cat esophageal circular smooth muscle cells. | 2001 Apr |
|
| Dantrolene inhibition of ryanodine receptor Ca2+ release channels. Molecular mechanism and isoform selectivity. | 2001 Apr 27 |
|
| Potent inhibition of NFAT activation and T cell cytokine production by novel low molecular weight pyrazole compounds. | 2001 Dec 21 |
|
| Extracellular calcium-sensing receptor is expressed in rat hepatocytes. coupling to intracellular calcium mobilization and stimulation of bile flow. | 2001 Feb 9 |
|
| Cloning and characterization of a novel human histamine receptor. | 2001 Mar |
|
| Activation of functional oxytocin receptors stimulates cell proliferation in human trophoblast and choriocarcinoma cell lines. | 2001 Mar |
|
| Histamine induces exocytosis and IL-6 production from human lung macrophages through interaction with H1 receptors. | 2001 Mar 15 |
|
| Tight control of exogenous SERCA expression is required to obtain acceleration of calcium transients with minimal cytotoxic effects in cardiac myocytes. | 2001 Mar 2 |
|
| RGS4 inhibits platelet-activating factor receptor phosphorylation and cellular responses. | 2001 Mar 27 |
|
| Oxidative impairment in scrapie-infected mice is associated with brain metals perturbations and altered antioxidant activities. | 2001 Nov |
|
| Activating mutations of the calcium-sensing receptor: management of hypocalcemia. | 2001 Nov |
|
| Molecular cloning and functional characterization of murine cysteinyl-leukotriene 1 (CysLT(1)) receptors. | 2001 Nov 1 |
|
| Hypoxia-induced regulation of MAPK phosphatase-1 as identified by subtractive suppression hybridization and cDNA microarray analysis. | 2001 Nov 30 |
|
| Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. | 2001 Oct |
|
| Familial intrahepatic cholestasis 1: studies of localization and function. | 2001 Oct |
|
| Microarray analysis of differential gene expression in lead-exposed astrocytes. | 2001 Oct 1 |
|
| Replacement of the muscle-specific sarcoplasmic reticulum Ca(2+)-ATPase isoform SERCA2a by the nonmuscle SERCA2b homologue causes mild concentric hypertrophy and impairs contraction-relaxation of the heart. | 2001 Oct 26 |
|
| Effects of vitamin D receptor inactivation on the expression of calbindins and calcium metabolism. | 2001 Sep |
|
| The role of endogenous human Trp4 in regulating carbachol-induced calcium oscillations in HEK-293 cells. | 2002 Apr 19 |
|
| Interaction of intravenous anesthetics with recombinant human M1-M3 muscarinic receptors expressed in chinese hamster ovary cells. | 2002 Dec |
|
| Characterization of basolateral K+ channels underlying anion secretion in the human airway cell line Calu-3. | 2002 Feb 1 |
|
| Characterization of the bone-resorptive effect of interleukin-11 in cultured mouse calvarial bones. | 2002 Jul |
|
| Delayed asystolic cardiac arrest after diltiazem overdose; resuscitation with high dose intravenous calcium. | 2002 Jul |
|
| Transcriptional induction of CYP1A1 by oltipraz in human Caco-2 cells is aryl hydrocarbon receptor- and calcium-dependent. | 2002 Jul 5 |
|
| Human kidney diamine oxidase: heterologous expression, purification, and characterization. | 2002 Jun |
|
| Hypertension-related intermyocyte junction remodelling is associated with a higher incidence of low-K(+)-induced lethal arrhythmias in isolated rat heart. | 2002 Mar |
|
| Alpha(1H) mRNA in single skeletal muscle fibres accounts for T-type calcium current transient expression during fetal development in mice. | 2002 Mar 15 |
|
| Diacylglycerol activates the influx of extracellular cations in T-lymphocytes independently of intracellular calcium-store depletion and possibly involving endogenous TRP6 gene products. | 2002 May 15 |
|
| Neuronal apoptosis inhibitory protein: Structural requirements for hippocalcin binding and effects on survival of NGF-dependent sympathetic neurons. | 2002 Nov 4 |
|
| Inhibition of peroxisome proliferator-activated receptor (PPAR)-mediated keratinocyte differentiation by lipoxygenase inhibitors. | 2002 Sep 15 |
|
| Dietary interventions for mineral and bone disorder in people with chronic kidney disease. | 2015 Sep 16 |
Sample Use Guides
Proper administration of calcium carbonate or phosphate: Taking tablets 1 to 11/2 hours after meals, unless otherwise directed by physician. Recommended doses for adolescents and adults is 800-1200 mg/day; for pregnat orbreast-feeding females 1200 mg/day.
Route of Administration:
Oral
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 19:57:24 GMT 2025
by
admin
on
Mon Mar 31 19:57:24 GMT 2025
|
| Record UNII |
492G10Q871
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
WHO-VATC |
QA12AA11
Created by
admin on Mon Mar 31 19:57:24 GMT 2025 , Edited by admin on Mon Mar 31 19:57:24 GMT 2025
|
||
|
WHO-ATC |
A12AA11
Created by
admin on Mon Mar 31 19:57:24 GMT 2025 , Edited by admin on Mon Mar 31 19:57:24 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
74078-13-0
Created by
admin on Mon Mar 31 19:57:24 GMT 2025 , Edited by admin on Mon Mar 31 19:57:24 GMT 2025
|
NON-SPECIFIC STOICHIOMETRY | |||
|
11041-98-8
Created by
admin on Mon Mar 31 19:57:24 GMT 2025 , Edited by admin on Mon Mar 31 19:57:24 GMT 2025
|
SUPERSEDED | |||
|
76966485
Created by
admin on Mon Mar 31 19:57:24 GMT 2025 , Edited by admin on Mon Mar 31 19:57:24 GMT 2025
|
PRIMARY | |||
|
1917
Created by
admin on Mon Mar 31 19:57:24 GMT 2025 , Edited by admin on Mon Mar 31 19:57:24 GMT 2025
|
PRIMARY | RxNorm | ||
|
C105565
Created by
admin on Mon Mar 31 19:57:24 GMT 2025 , Edited by admin on Mon Mar 31 19:57:24 GMT 2025
|
PRIMARY | |||
|
SUB14752MIG
Created by
admin on Mon Mar 31 19:57:24 GMT 2025 , Edited by admin on Mon Mar 31 19:57:24 GMT 2025
|
PRIMARY | |||
|
100000079718
Created by
admin on Mon Mar 31 19:57:24 GMT 2025 , Edited by admin on Mon Mar 31 19:57:24 GMT 2025
|
PRIMARY | |||
|
DB13590
Created by
admin on Mon Mar 31 19:57:24 GMT 2025 , Edited by admin on Mon Mar 31 19:57:24 GMT 2025
|
PRIMARY | |||
|
4385
Created by
admin on Mon Mar 31 19:57:24 GMT 2025 , Edited by admin on Mon Mar 31 19:57:24 GMT 2025
|
PRIMARY | |||
|
CALCIUM PANGAMATE
Created by
admin on Mon Mar 31 19:57:24 GMT 2025 , Edited by admin on Mon Mar 31 19:57:24 GMT 2025
|
PRIMARY | |||
|
20310-61-6
Created by
admin on Mon Mar 31 19:57:24 GMT 2025 , Edited by admin on Mon Mar 31 19:57:24 GMT 2025
|
PRIMARY | |||
|
492G10Q871
Created by
admin on Mon Mar 31 19:57:24 GMT 2025 , Edited by admin on Mon Mar 31 19:57:24 GMT 2025
|
PRIMARY | |||
|
DTXSID80891357
Created by
admin on Mon Mar 31 19:57:24 GMT 2025 , Edited by admin on Mon Mar 31 19:57:24 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
